Literature DB >> 26299230

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

Eldrin F Lewis1, Brian Claggett2, Patrick S Parfrey3, Emmanuel A Burdmann4, John J V McMurray5, Scott D Solomon2, Andrew S Levey6, Peter Ivanovich7, Kai-Uwe Eckardt8, Reshma Kewalramani9, Robert Toto10, Marc A Pfeffer2.   

Abstract

BACKGROUND: The incidence of end-stage renal disease (ESRD) has been consistently shown to be higher among blacks and Hispanics compared to whites with unmeasured risk factors and access to care as suggested explanations. In a high-risk cohort with frequent protocol-directed follow-up, we evaluated the influence of race on cardiovascular (CV) outcomes and incidence of ESRD.
METHODS: TREAT was a randomized, double-blind, placebo-controlled study. This secondary analysis focused on role of race on outcomes. TREAT enrolled 4,038 patients with type 2 diabetes, chronic kidney disease (estimated glomerular filtration rate 20-60 mL/min per 1.73 m(2)), and anemia (hemoglobin level ≤11 g/dL) treated with either darbepoetin alfa or placebo. We compared self-described black and Hispanic patients to white patients with regard to baseline characteristics and outcomes, including mortality, CV outcomes (myocardial infarction, stroke, heart failure, resuscitated sudden death, and coronary revascularization), and incident ESRD. Multivariate adjusted Cox models were developed for these outcomes.
RESULTS: Black and Hispanic patients were younger, more likely women, had less prior CV disease, and higher blood pressure. During a mean follow-up of 2.4 years with comparable access to care, blacks and Hispanics had a greater risk of ESRD but a significant lower risk of myocardial infarction and coronary revascularization than whites. After adjusting for confounders, blacks remained at significantly greater risk of ESRD than whites (hazard ratio 1.53, 95% CI 1.26-1.85, P < .001), whereas this ESRD risk did not persist among Hispanics.
CONCLUSION: Despite similar access to care and lower CV event rates, the risk of ESRD was higher among blacks and Hispanics than whites. For blacks, but not Hispanics, this increase was independent of known attributable risk factors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26299230     DOI: 10.1016/j.ahj.2015.05.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

1.  Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes.

Authors:  Claire Gerber; Xuan Cai; Jungwha Lee; Timothy Craven; Julia Scialla; Nao Souma; Anand Srivastava; Rupal Mehta; Amanda Paluch; Alexander Hodakowski; Rebecca Frazier; Mercedes R Carnethon; Myles Selig Wolf; Tamara Isakova
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-24       Impact factor: 8.237

Review 2.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

3.  Disparities in diabetes-related multiple chronic conditions and mortality: The influence of race.

Authors:  John M Clements; Brady T West; Zachary Yaker; Breanna Lauinger; Deven McCullers; James Haubert; Mohammad Ali Tahboub; Gregory J Everett
Journal:  Diabetes Res Clin Pract       Date:  2019-12-15       Impact factor: 5.602

4.  Race and sex differences in rates of diabetic complications.

Authors:  Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ping Yin; Alessandra N Bazzano; Somesh Nigam; Gang Hu
Journal:  J Diabetes       Date:  2018-11-13       Impact factor: 4.006

Review 5.  Diabetes Complications in Racial and Ethnic Minority Populations in the USA.

Authors:  J Sonya Haw; Megha Shah; Sara Turbow; Michelle Egeolu; Guillermo Umpierrez
Journal:  Curr Diab Rep       Date:  2021-01-09       Impact factor: 4.810

Review 6.  CKD and ESRD in US Hispanics.

Authors:  Nisa Desai; Claudia M Lora; James P Lash; Ana C Ricardo
Journal:  Am J Kidney Dis       Date:  2018-04-13       Impact factor: 8.860

7.  Racial differences in all-cause mortality and future complications among people with diabetes: a systematic review and meta-analysis of data from more than 2.4 million individuals.

Authors:  Yasmin Ezzatvar; Robinson Ramírez-Vélez; Mikel Izquierdo; Antonio García-Hermoso
Journal:  Diabetologia       Date:  2021-08-28       Impact factor: 10.122

8.  Geographic disparities in mortality among the end stage renal disease patients: an analysis of the United States Renal Data System, 2007-08.

Authors:  Fozia Ajmal; Kevin J Bennett; Janice C Probst
Journal:  J Nephrol       Date:  2016-06-16       Impact factor: 3.902

9.  Black Race Is Associated With Higher Rates of Early-Onset End-Stage Renal Disease and Increased Mortality Following Liver Transplantation.

Authors:  Meagan Alvarado; Douglas E Schaubel; K Rajender Reddy; Therese Bittermann
Journal:  Liver Transpl       Date:  2021-04-21       Impact factor: 6.112

10.  Ethnic differences in the progression of chronic kidney disease and risk of death in a UK diabetic population: an observational cohort study.

Authors:  Rohini Mathur; Gavin Dreyer; Magdi M Yaqoob; Sally A Hull
Journal:  BMJ Open       Date:  2018-03-27       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.